Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics, 2012
2012 · External reference
Pancreatic cancer
10.1067/mcn.2002.129579 · 2002 · External reference
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial
10.1200/jco.2011.34.8904 · 2011 · External reference
Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil – an Eastern Cooperative Oncology Group study
10.1200/jco.1985.3.3.373 · 1985 · External reference
10.1093/annonc/mdn281
10.1093/annonc/mdn281 · 2008 · External reference
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma
10.1002/cncr.29161 · 2015 · External reference
Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer
10.1016/j.ijrobp.2003.11.004 · 2004 · External reference
Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma
10.1016/j.radonc.2004.12.022 · 2005 · External reference
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer
10.1016/j.ijrobp.2005.07.002 · 2005 · External reference
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer
10.1016/j.ijrobp.2008.01.051 · 2008 · External reference
Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer
10.1016/j.ijrobp.2009.08.046 · 2010 · External reference
Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas
10.1097/coc.0b013e3181d270b4 · 2011 · External reference
Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer
10.1016/j.ijrobp.2010.05.006 · 2011 · External reference
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: A pilot trial demonstrating safety
10.1186/1748-717x-8-44 · 2013 · External reference
Stereotactic body radiotherapy in the treatment of pancreatic cancer
10.1016/j.semradonc.2013.11.008 · 2014 · External reference
Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: Outcomes and toxicity
10.1016/j.ijrobp.2014.06.066 · 2014 · External reference
Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial
10.1001/jama.2016.4324 · 2016 · External reference
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
10.1093/jnci/92.3.205 · 2000 · External reference
From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors
10.2967/jnumed.108.057307 · 2009 · External reference
Unresolved reference
2010 · External reference
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer
10.1200/jco.2008.17.7188 · 2009 · External reference
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
10.1056/nejmoa1304369 · 2013 · External reference
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
10.1056/nejmoa1011923 · 2011 · External reference
Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: Experience from two institutions
2013 · External reference
High expression of muscarinic acetylcholine receptor 3 predicts poor prognosis in patients with pancreatic ductal adenocarcinoma
10.2147/ott.s111382 · 2016 · External reference
Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas
10.1007/s13277-016-5061-7 · 2016 · External reference
10.1001/jamaoncol.2016.3916
10.1001/jamaoncol.2016.3916 · External reference
Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma
10.1002/cncr.25481 · 2010 · External reference
Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas
10.1186/1748-717x-7-74 · 2012 · External reference
